SecBot SecBot
8-K ·Filed Jun 16, 2026

ARWR

ARROWHEAD PHARMACEUTICALS, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0000879407-26-000050
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine board appointment with no immediate trading catalyst. Monitor for any strategic shifts given Cohen's deep healthcare investing background, but no near-term action warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$81.04
T+0 close · Jun 16, 2026 · via day close
Latest settled
+2.23%
T+60 · $82.85
Vs SPY
−0.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 17 $81.04entry
  2. T+1 · 5mo ago +0.96%α +0.18% · $81.82
  3. T+5 · 5mo ago −1.52%α −0.48% · $79.81
  4. T+20 · 4mo ago −11.93%α −13.24% · $71.38
  5. T+60 · 2mo ago +2.23%α −0.92% · $82.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arrowhead Pharmaceuticals appointed Dr. Matt Cohen, a seasoned healthcare investor and former JP Morgan portfolio manager, to its board of directors effective June 12, 2026. The appointment is routine with standard non-employee director compensation and a sign-on RSU grant of $887,000 vesting over three years.

Key Facts

  • Dr. Matt Cohen appointed as director effective June 12, 2026
  • Cohen brings 25+ years of healthcare investing experience, currently Managing Director at Vida Ventures
  • Sign-on RSU grant valued at $887,000 vesting over three years
  • Standard non-employee director compensation; no family relationships or arrangements

Financial Impact

No material financial impact; sign-on RSU grant of $887,000 is standard director compensation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000879407-26-000050
Document: 0000879407-26-000050-index-headers.html0000879407-26-000050
Document: 0000879407-26-000050-index.html0000879407-26-000050
Document: 0000879407-26-000050.txt0000879407-26-000050

Track record

7 reports on ARWR

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +17.69% at T+5 after the Nov 2, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $47.78 to $44.21 Now $44.21 +7.47% ▲ +7.47% +5.56% vs SPY
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $57.46 to $58.16 Now $44.21 −23.06% ▲ +1.22% +0.91% vs SPY
  3. Nov 4, 202612d ago 8-K Bullish 5/10 Entry $61.65 to $57.46 Now $44.21 −28.29% ▼ −6.80% −2.39% vs SPY
  4. Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $59.53 to $61.65 Now $44.21 +25.73% ▼ −3.56% −1.91% vs SPY
  5. Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $82.76 to $82.85 Now $44.21 −46.58% ▲ +0.11% −0.74% vs SPY
  6. Aug 20, 202612w ago Insider Cluster Neutral 2/10 Entry $87.11 to $86.73 Now $44.21 −49.25% ▼ −0.44% −0.14% vs SPY
  7. Jun 16, 202621w ago 8-K Neutral 2/10 Viewing Entry $81.04 to $81.82 Now $44.21 −45.45% ▲ +0.96% +0.18% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens Wed (11h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026